IMVT Immunovant

Immunovant to Present at Upcoming Investor Conferences

Immunovant to Present at Upcoming Investor Conferences

NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., chief executive officer, will participate in fireside chats at the following investor conferences:

Stifel 2023 Healthcare Conference on Wednesday, November 15, 2023, at 1:50 pm ET

Evercore ISI 6th Annual HealthCONx Conference on Tuesday, November 28, 2023, at 5:05 pm ET

Piper Sandler 35th Annual Healthcare Conference on Thursday, November 30, 2023, at 11:30 am ET

The fireside chats will be webcast live and can be accessed at . An archived webcast will be available for a limited time on Immunovant’s website.

About Immunovant, Inc.

Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit . 

Contact:

Chau Cheng, PhD, MBA

Vice President, Investor Relations

Immunovant, Inc.

Jaye Bea Smalley

Head, Patient Advocacy

Immunovant, Inc.



EN
13/11/2023

Underlying

IMVTImmunovant

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Immunovant

 PRESS RELEASE
Free
IMVT IMMUNOVANT

Immunovant Provides Corporate Updates and Reports Financial Results fo...

Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025 IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from the proof-of-concept trial in cutaneous lupus erythematosus (CLE) expected in the second half of calendar year 2026IMVT-1402 development is progressing with potentially registrational studies in Graves’ disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuro...

February 6, 2026 1 EN
 PRESS RELEASE
Free
IMVT IMMUNOVANT

Immunovant to Report Financial Results for the Third Quarter Ended Dec...

Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 DURHAM, N.C. and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the third quarter ended December 31, 2025, and provide a business update at 8:00 a.m. ET on Friday, February 6, 2026. To access the Roivant (Nasdaq: ROIV) conference call by phone, please register online using this . The presentation and webcast details will also be available under “News & Events” in t...

January 23, 2026 1 EN
 PRESS RELEASE
Free
IMVT IMMUNOVANT

Immunovant Announces Pricing of $550 Million Common Stock Financing

Immunovant Announces Pricing of $550 Million Common Stock Financing Funding to provide runway through potential Graves’ Disease commercial launch NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the pricing of an underwritten offering of its common stock, with anticipated gross proceeds to Immunovant of approximately $550 million, before deducting underwriting discounts and commissions and other expenses payable by Immunovant in connectio...

December 11, 2025 1 EN
 PRESS RELEASE
Free
IMVT IMMUNOVANT

Immunovant Provides Corporate Updates and Reports Financial Results fo...

Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025 Study in uncontrolled Graves’ disease (GD) patients treated for 24 weeks showed first-ever potentially disease-modifying outcome with six-month off-treatment dataIMVT-1402 development is progressing with potentially registrational studies in GD, myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), difficult-to-treat rheumatoid arthritis (D2T RA) and Sjögren’s disease (SjD) remains on trackImmunovant remains on track for the first of the two batocli...

November 10, 2025 1 EN
 PRESS RELEASE
Free
IMVT IMMUNOVANT

Immunovant to Report Financial Results for the Second Quarter Ended Se...

Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the second quarter ended September 30, 2025, and provide a business update at 8:00 a.m. ET on Monday, November 10, 2025. To access the Roivant (Nasdaq: ROIV) conference call by phone, please register online using this . The presentation and webcast details will also be available under “News & Events” in the Investor...

October 27, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch